MedTrace Logo

Individual Patient Compassionate Use of Mirdametinib

NCT05028166 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-05-08

No results posted yet for this study

Summary

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

Conditions

  • Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
  • Histiocytic Neoplasm
  • Other MAP-K Pathway Driven Diseases

Interventions

DRUG

Mirdametinib (MEK Inhibitor)

Patients will receive oral mirdametinib.

Sponsors & Collaborators

  • SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05028166 on ClinicalTrials.gov